注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Caribou Biosciences Inc是一家臨床階段基因組編輯生物製藥公司。該公司正在為患有毀滅性疾病的患者開發具有變革性的聚集性定期間隔短回文重複序列(CRISPR)療法。該公司的CRISPR平台CRISPR hybrid RNA-DNA(chRDNA)能夠實現卓越的基因組編輯精度,以開發專門設計用於增強持久性的細胞療法。它正在推進一系列異基因或現成的嵌合抗原受體(CAR)-T(CAR-T)和CAR自然殺傷(CAR-NK)細胞療法,用於治療血液系統惡性腫瘤和實體瘤患者。其主要候選產品CB-010是一種臨床階段異基因抗CD19 CAR-T細胞療法,通過對PDCDI基因進行基因組編輯敲除,從CAR-T細胞表面去除程序性細胞死亡蛋白1(PD-1)。該公司的候選產品還包括CB-011、CB-012和CB-012。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Rachel E. Haurwitz | 36 | 2011 | Co-Founder, CEO, President & Director |
Martin Jinek | - | - | Member of Scientific Advisory Board |
Andrew L. Guggenhime | 54 | 2021 | Independent Chairman |
Katy Rezvani | - | - | Member of Scientific Advisory Board |
Scott N. Braunstein | 59 | 2021 | Independent Director |
Jennifer A. Doudna | 58 | - | Member of Scientific Advisory Board |
Cameron J. Turtle | - | - | Member of Scientific Advisory Board |
Natalie R. Sacks | 57 | 2018 | Independent Director |
Noopur Raje | - | - | Member of Scientific Advisory Board |
Dara Richardson-Heron | 59 | 2021 | Independent Director |
Ami Bhatt | - | - | Member of Scientific Advisory Board |
Ran Zheng | 59 | 2021 | Independent Director |
Nancy Whiting | 50 | 2021 | Independent Director |
David Lee Johnson | 54 | 2022 | Independent Director |
Stephen J. Schuster | - | 2023 | Member of Scientific Advisory Board |
Sundar Jagannath | - | 2023 | Member of Scientific Advisory Board |
Akos Czibere | - | 2024 | Member of Scientific Advisory Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核